Literature DB >> 21491194

Current treatment options for pancreatic carcinoma.

Emily Castellanos1, Jordan Berlin, Dana Backlund Cardin.   

Abstract

Pancreas cancer is a significant cause of cancer mortality; therefore, the development of early diagnostic strategies and effective treatment is essential. Improvements in imaging technology, as well as use of biomarkers such as CA 19-9, are changing the way that pancreas cancer is diagnosed and staged. Although progress in treatment for pancreas cancer has been incremental, development of combination therapies involving both chemotherapeutic and biologic agents is ongoing. This article reviews current strategies in the diagnosis and treatment of resectable and advanced pancreas cancer.

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21491194     DOI： 10.1007/s11912-011-0164-1

Source DB:  PubMed          Journal:  Curr Oncol Rep        ISSN： 1523-3790            Impact factor:   5.075


  56 in total

1.  Liposomal cisplatin combined with gemcitabine in pretreated advanced pancreatic cancer patients: a phase I-II study.

Authors:  George P Stathopoulos; Teni Boulikas; Maria Vougiouka; Sotirios K Rigatos; John G Stathopoulos
Journal:  Oncol Rep       Date:  2006-05       Impact factor: 3.906

2.  Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial.

Authors:  Helmut Oettle; Stefan Post; Peter Neuhaus; Klaus Gellert; Jan Langrehr; Karsten Ridwelski; Harald Schramm; Joerg Fahlke; Carl Zuelke; Christof Burkart; Klaus Gutberlet; Erika Kettner; Harald Schmalenberg; Karin Weigang-Koehler; Wolf-Otto Bechstein; Marco Niedergethmann; Ingo Schmidt-Wolf; Lars Roll; Bernd Doerken; Hanno Riess
Journal:  JAMA       Date:  2007-01-17       Impact factor: 56.272

3.  Combined modality treatment of resectable and borderline resectable pancreas cancer: expert consensus statement.

Authors:  Ross A Abrams; Andrew M Lowy; Eileen M O'Reilly; Robert A Wolff; Vincent J Picozzi; Peter W T Pisters
Journal:  Ann Surg Oncol       Date:  2009-04-24       Impact factor: 5.344

4.  Phase I study of weekly gemcitabine as a radiation sensitizer for unresectable pancreatic cancer.

Authors:  Matthew M Poggi; Glenn S Kroog; Angelo Russo; Christine Muir; John Cook; Judith Smith; James B Mitchell; Laurie L Herscher
Journal:  Int J Radiat Oncol Biol Phys       Date:  2002-11-01       Impact factor: 7.038

5.  High efficacy of gemcitabine and cisplatin in patients with predominantly anthracycline- and taxane-pretreated metastatic breast cancer.

Authors:  V Heinemann; H J Stemmler; A Wohlrab; D Bosse; C Losem; S Kahlert; G Rauthe
Journal:  Cancer Chemother Pharmacol       Date:  2005-09-15       Impact factor: 3.333

6.  Phase III study comparing gemcitabine plus cetuximab versus gemcitabine in patients with advanced pancreatic adenocarcinoma: Southwest Oncology Group-directed intergroup trial S0205.

Authors:  Philip A Philip; Jacqueline Benedetti; Christopher L Corless; Ralph Wong; Eileen M O'Reilly; Patrick J Flynn; Kendrith M Rowland; James N Atkins; Barry C Mirtsching; Saul E Rivkin; Alok A Khorana; Bryan Goldman; Cecilia M Fenoglio-Preiser; James L Abbruzzese; Charles D Blanke
Journal:  J Clin Oncol       Date:  2010-07-06       Impact factor: 44.544

Review 7.  Borderline resectable pancreatic cancer: on the edge of survival.

Authors:  Gregory M Springett; Sarah E Hoffe
Journal:  Cancer Control       Date:  2008-10       Impact factor: 3.302

8.  Full-dose gemcitabine with concurrent radiation therapy in patients with nonmetastatic pancreatic cancer: a multicenter phase II trial.

Authors:  William Small; Jordan Berlin; Gary M Freedman; Theodore Lawrence; Mark S Talamonti; Mary F Mulcahy; A Bapsi Chakravarthy; Andre A Konski; Mark M Zalupski; Philip A Philip; Timothy J Kinsella; Nipun B Merchant; John P Hoffman; Al B Benson; Steven Nicol; Rong M Xu; John F Gill; Cornelius J McGinn
Journal:  J Clin Oncol       Date:  2008-02-20       Impact factor: 44.544

9.  A prospective diagnostic accuracy study of 18F-fluorodeoxyglucose positron emission tomography/computed tomography, multidetector row computed tomography, and magnetic resonance imaging in primary diagnosis and staging of pancreatic cancer.

Authors:  Saila P Kauhanen; Gaber Komar; Marko P Seppänen; Kirsti I Dean; Heikki R Minn; Sami A Kajander; Irina Rinta-Kiikka; Kalle Alanen; Ronald J Borra; Pauli A Puolakkainen; Pirjo Nuutila; Jari T Ovaska
Journal:  Ann Surg       Date:  2009-12       Impact factor: 12.969

10.  Pancreaticoduodenectomy for cancer of the head of the pancreas. 201 patients.

Authors:  C J Yeo; J L Cameron; K D Lillemoe; J V Sitzmann; R H Hruban; S N Goodman; W C Dooley; J Coleman; H A Pitt
Journal:  Ann Surg       Date:  1995-06       Impact factor: 12.969
View more
  18 in total

1.  Multifunctional thiosemicarbazones and deconstructed analogues as a strategy to study the involvement of metal chelation, Sigma-2 (σ2) receptor and P-gp protein in the cytotoxic action: In vitro and in vivo activity in pancreatic tumors.

Authors:  Maria Laura Pati; Mauro Niso; Dirk Spitzer; Francesco Berardi; Marialessandra Contino; Chiara Riganti; William G Hawkins; Carmen Abate
Journal:  Eur J Med Chem       Date:  2017-12-08       Impact factor: 6.514

2.  Single-cell RNA-seq highlights intra-tumoral heterogeneity and malignant progression in pancreatic ductal adenocarcinoma.

Authors:  Junya Peng; Bao-Fa Sun; Chuan-Yuan Chen; Jia-Yi Zhou; Yu-Sheng Chen; Hao Chen; Lulu Liu; Dan Huang; Jialin Jiang; Guan-Shen Cui; Ying Yang; Wenze Wang; Dan Guo; Menghua Dai; Junchao Guo; Taiping Zhang; Quan Liao; Yi Liu; Yong-Liang Zhao; Da-Li Han; Yupei Zhao; Yun-Gui Yang; Wenming Wu
Journal:  Cell Res       Date:  2019-07-04       Impact factor: 25.617

3.  Carbohydrate antigen 19-9 is a prognostic and predictive biomarker in patients with advanced pancreatic cancer who receive gemcitabine-containing chemotherapy: a pooled analysis of 6 prospective trials.

Authors:  Todd M Bauer; Bassel F El-Rayes; Xiaobai Li; Nazik Hammad; Philip A Philip; Anthony F Shields; Mark M Zalupski; Tanios Bekaii-Saab
Journal:  Cancer       Date:  2012-07-11       Impact factor: 6.860

4.  Biological Characterization and Clinical Value of OAS Gene Family in Pancreatic Cancer.

Authors:  Li-Juan Gao; Jia-Lei Li; Rui-Rui Yang; Zhong-Mei He; Min Yan; Xia Cao; Ji-Min Cao
Journal:  Front Oncol       Date:  2022-06-03       Impact factor: 5.738

Review 5.  Pancreatic cancer biology and genetics from an evolutionary perspective.

Authors:  Alvin Makohon-Moore; Christine A Iacobuzio-Donahue
Journal:  Nat Rev Cancer       Date:  2016-07-22       Impact factor: 60.716

6.  Glaucarubinone and gemcitabine synergistically reduce pancreatic cancer growth via down-regulation of P21-activated kinases.

Authors:  Dannel Yeo; Nhi Huynh; John A Beutler; Christopher Christophi; Arthur Shulkes; Graham S Baldwin; Mehrdad Nikfarjam; Hong He
Journal:  Cancer Lett       Date:  2014-01-31       Impact factor: 8.679

7.  Predictive implications of decreased CA19-9 at 8 weeks during nab-paclitaxel plus gemcitabine for the induction of second-line chemotherapy for patients with advanced pancreatic cancer.

Authors:  Kiyotsugu Iede; Terumasa Yamada; Ryo Kato; Masami Ueda; Yujiro Tsuda; Shinsuke Nakashima; Katsuya Ohta; Jin Matsuyama; Masakazu Ikenaga; Shusei Tominaga
Journal:  Cancer Rep (Hoboken)       Date:  2020-09-23

8.  Establishment, characterization and chemosensitivity of three mismatch repair deficient cell lines from sporadic and inherited colorectal carcinomas.

Authors:  Claudia Maletzki; Saskia Stier; Ulrike Gruenert; Michael Gock; Christiane Ostwald; Friedrich Prall; Michael Linnebacher
Journal:  PLoS One       Date:  2012-12-31       Impact factor: 3.240

Review 9.  Chemotherapy and radiotherapy for advanced pancreatic cancer.

Authors:  Venessa Chin; Adnan Nagrial; Katrin Sjoquist; Chelsie A O'Connor; Lorraine Chantrill; Andrew V Biankin; Rob Jpm Scholten; Desmond Yip
Journal:  Cochrane Database Syst Rev       Date:  2018-03-20

10.  CA19-9 decrease at 8 weeks as a predictor of overall survival in a randomized phase III trial (MPACT) of weekly nab-paclitaxel plus gemcitabine versus gemcitabine alone in patients with metastatic pancreatic cancer.

Authors:  E G Chiorean; D D Von Hoff; M Reni; F P Arena; J R Infante; V G Bathini; T E Wood; P N Mainwaring; R T Muldoon; P R Clingan; V Kunzmann; R K Ramanathan; J Tabernero; D Goldstein; D McGovern; B Lu; A Ko
Journal:  Ann Oncol       Date:  2016-01-22       Impact factor: 32.976
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.